Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04516655` - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients	Phase 2
Recruiting	`NCT05054426` - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL	Phase 3
Recruiting	`NCT02623010` - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma	Phase 2
Recruiting	`NCT04548648` - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas	Phase 2
Active, not recruiting	`NCT00293475` - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Phase 1/Phase 2
Completed	`NCT03342586` - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated	`NCT02420795` - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Completed	`NCT01011920` - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma	Phase 2
Completed	`NCT00967200` - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors	N/A
Recruiting	`NCT03684980` - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma	Early Phase 1
Not yet recruiting	`NCT06213636` - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).	Phase 1/Phase 2
Recruiting	`NCT04938297` - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma	Phase 2
Recruiting	`NCT04792489` - DALY II USA/ MB-CART2019.1 for DLBCL	Phase 2
Completed	`NCT01458730` - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma	Phase 2
Completed	`NCT00153530` - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)	Phase 4
Recruiting	`NCT04186520` - CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies	Phase 1/Phase 2
Recruiting	`NCT05816746` - Decitabine and Anti-PD-1 in R/R DLBCL	Phase 2
Recruiting	`NCT06031194` - Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Active, not recruiting	`NCT03962127` - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Completed	`NCT03690895` - Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy

NCT number	NCT05209620
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Zhihua Yao, M.D. Ph.D
Phone	+8613592622292
Email	zlyyyaozhihua1260@zzu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	December 21, 2021
Completion date	December 21, 2026

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms